WEN Yandong,YANG Zhi,HUANG Shaogang,et al.Current Status,Strategies and Prospects of Traditional Chinese Medicine Diagnosis and Treatment for Irritable Bowel Syndrome[J].Journal of Traditional Chinese Medicine,2026,67(04):404-409.
WEN Yandong,YANG Zhi,HUANG Shaogang,et al.Current Status,Strategies and Prospects of Traditional Chinese Medicine Diagnosis and Treatment for Irritable Bowel Syndrome[J].Journal of Traditional Chinese Medicine,2026,67(04):404-409.DOI: 10.13288/j.11-2166/r.2026.04.011.
Current Status,Strategies and Prospects of Traditional Chinese Medicine Diagnosis and Treatment for Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a functional bowel disorder characterized primarily by abdominal pain and altered defecation habits. In recent years, traditional Chinese medicine (TCM) has made progress in multiple aspects of IBS research and treatment, including syndrome distribution, development of TCM formulas, clinical efficacy evaluation, external therapies, and psychosocial regulation. However, it still faces challenges such as over-reliance on symptomatic manifestations rather than biomarkers for diagnostic criteria, and the lack of high-quality evidence-based data supporting the efficacy of TCM formulas in treating IBS. This paper proposed that TCM diagnosis and treatment of IBS should adhere to the strategy of integrating the holistic concept with syndrome differentiation and treatment, combining TCM external therapies such as acupuncture, moxibustion and acupoint application), and emphasizing individualized diagnosis and treatment for psychosomatic abnormalities. Future research should integrate multi-omics technologies, artificial intelligence and other methods to deepen the understanding of the pathogenesis of IBS and the mechanisms of TCM formulas, so as to promote the standardization and internationalization of TCM in the diagnosis and treatment of IBS.
关键词
Keywords
references
MEARIN F , LACY BE , CHANG L , et al . Bowel disorders [J]. Gastroenterology , 2016 , 18 : S0016-5085(16)00222 - 5 . doi: 10.1053/j.gastro.2016.02.031 http://dx.doi.org/10.1053/j.gastro.2016.02.031 .
ALMARIO CV , SHARABI E , CHEY WD , et al . Prevalence and burden of illness of Rome Ⅳ irritable bowel syndrome in the United States: results from a nationwide cross-sectional study [J]. Gastroenterology , 2023 , 165 ( 6 ): 1475 - 1487 .
OKA P , PARR H , BARBERIO B , et al . Global prevalence of irritable bowel syndrome according to Rome Ⅲ or Ⅳ criteria: a systematic review and meta-analysis [J]. Lancet Gastroenterol Hepatol , 2020 , 5 ( 10 ): 908 - 917 .
HANNA-JAIRALA I , DROSSMAN DA . Central neuromodulators in irritable bowel syndrome: why, how, and when [J]. Am J Gastroenterol , 2024 , 119 ( 7 ): 1272 - 1284 .
BARBARO MR , CREMON C , MARASCO G , et al . Mole-cular mechanisms underlying loss of vascular and epithelial integrity in irritable bowel syndrome [J]. Gastroenterology , 2024 , 167 ( 6 ): 1152 - 1166 .
SONG J , YANG L , SU S , et al . The diagnosis performance of the TCM syndromes of irritable bowel syndrome by gastroenterologists based on modified simple criteria compared to TCM practitioners: a prospective, multicenter preliminary study [J]. Evid Based Complement Alternat Med , 2020 , 2020 : 9507674 . doi: 10.1155/2020/9507674 http://dx.doi.org/10.1155/2020/9507674 .
TANG XD , ZHANG SS , HOU XH , et al . Post-marketing re-evaluation of Tongxiening granules in treatment of diarrhea-predominant irritable bowel syndrome: a multi-center, randomized, double-blind, double-dummy and positive control trial [J]. Chin J Integr Med , 2019 , 25 ( 12 ): 887 - 894 .
LACY BE , PIMENTEL M , BRENNER DM , et al . ACG clinical guideline: management of irritable bowel syndrome [J]. Am J Gastroenterol , 2021 , 116 ( 1 ): 17 - 44 .
YAO X , YANG YS , CUI LH , et al . The overlap of upper functional gastrointestinal disorders with irritable bowel syndrome in Chinese outpatients:a multicenter study [J]. J Gastroenterol Hepatol , 2016 , 31 ( 9 ): 1584 - 1593 .
HÄUSER W , MARSCHALL U , LAYER P , et al . The prevalence, comorbidity, management and costs of irritable bowel syndrome [J]. Dtsch Arztebl Int , 2019 , 116 ( 27/28 ): 463 - 470 .
VANDVIK PO , WILHELMSEN I , IHLEBAEK C , et al . Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications [J]. Aliment Pharmacol Ther , 2004 , 20 ( 10 ): 1195 - 1203 .
IRVINE AJ , CHER WD , FORD AC . Screening for celiac disease in irritable bowel syndrome: an updated systema-tic review and meta-analysis [J]. Am J Gastroenterol , 2017 , 112 ( 1 ): 65 - 76 .
DROSSMAN DA , HASLER WL . Rome Ⅳ functional GI disorders: disorders of gut brain interaction [J]. Gastroenterology , 2016 , 150 ( 6 ): 12571261 .
GWEE KA , GONLACHANVIT S , GHOSHAL UC , et al . Second Asian consensus on irritable bowel syndrome [J]. J Neurogastroenterol Motil , 2019 , 25 ( 3 ): 343 - 362 .
GWEE KA , LU CL , GHOSHAL UC . Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed [J]. J Gastroenterol Hepatol , 2009 , 24 ( 10 ): 1601 - 1607 .
KOLOSKI NA , JONES M , KALANTAR J , et al . The brain gut pathway in functional gastrointestinal disorders is bidirectional: a 12 year prospective population based study [J]. Gut , 2012 , 61 ( 9 ): 1284 - 1290 .
BLACK CJ , FORD AC . Irritable bowel syndrome:a spot⁃light on future research needs [J]. Lancet Gastroenterol Hepatol , 2021 , 6 ( 6 ): 419 - 422 .
ZHENG L , LU W , XIAO Q , et al . Assessing the post-treatment therapeutic effect of pinaverium in irritable bowel syndrome: a randomized controlled trial [J]. Sci Rep , 2021 , 11 ( 1 ): 13894 .
WEI X , WEN Y , WEI Y , et al . External therapy of traditional Chinese medicine for treating irritable bowel syndrome with diarrhea: a systematic review and meta-analysis [J]. Front Med (Lausanne) , 2022 , 9 : 940328 . doi: 10.3389/fmed.2022.940328 http://dx.doi.org/10.3389/fmed.2022.940328 .
EIJSBOUTS C , ZHENG T , KENNEDY NA , et al . Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders [J]. Nat Genet , 2021 , 53 ( 11 ): 1543 - 1552 .
Research Advances of Traditional Chinese Medicine Diagnosis and Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease:Overview and Prospects
Current Status and Prospects of Research on Traditional Chinese Medicine Prevention and Treatment for Gastric Precancerous Lesions
Overview of Diagnosis,Treatment and Mechanism Research of Functional Dyspepsia by Integrated Traditional Chinese and Western Medicine
Current Status and Strategies of Traditional Chinese Medicine in the Clinical Diagnosis and Treatment of Acute Pancreatitis
Current Status of Clinical and Basic Research on Traditional Chinese Medicine for Functional Constipation
Related Author
DAI Liang
JI Guang
WANG Xianbo
ZHANG Li
XU Hanchen
BAI Haiyan
ZHANG Tai
WANG Ping
Related Institution
Longhua Hospital,Shanghai University of Traditional Chinese Medicine
Institute of Digestive Diseases, Shanghai University of Traditional Chinese Medicine
Beijing Ditan Hospital,Capital Medical University
Hebei Hospital of Traditional Chinese Medicine
School of Clinical Medicine of Traditional Chinese Medicine (Xiyuan),Peking University